BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 25308294)

  • 1. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes.
    Benjamini O; Jain P; Trinh L; Qiao W; Strom SS; Lerner S; Wang X; Burger J; Ferrajoli A; Kantarjian H; O'Brien S; Wierda W; Estrov Z; Keating M
    Leuk Lymphoma; 2015 Jun; 56(6):1643-50. PubMed ID: 25308294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Zhou Y; Tang G; Medeiros LJ; McDonnell TJ; Keating MJ; Wierda WG; Wang SA
    Mod Pathol; 2012 Feb; 25(2):237-45. PubMed ID: 22080061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.
    Colović M; Suvajdžić N; Janković G; Tomin D; Colović N; Fekete MD; Palibrk V
    Biomed Pharmacother; 2011 Aug; 65(5):319-21. PubMed ID: 21775097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
    Morrison VA; Rai KR; Peterson BL; Kolitz JE; Elias L; Appelbaum FR; Hines JD; Shepherd L; Larson RA; Schiffer CA
    J Clin Oncol; 2002 Sep; 20(18):3878-84. PubMed ID: 12228208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
    Short NJ; Keating MJ; Wierda WG; Faderl S; Ferrajoli A; Estrov Z; Smith SC; O'Brien SM
    Cancer; 2015 Nov; 121(21):3869-76. PubMed ID: 26218678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
    Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
    Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials.
    Joffe E; Goldschmidt N; Bairey O; Fineman R; Ruchlemer R; Rahimi-Levene N; Shvidel L; Greenbaum U; Aviv A; Tadmor T; Braester A; Arad A; Polliack A; Herishanu Y;
    Eur J Haematol; 2018 Sep; 101(3):399-406. PubMed ID: 29949186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy-related myelodysplastic syndrome/acute myeloid leukemia following fludarabine therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Thai patients.
    Niparuck P; Kanoksil W; Chuncharunee S; Boonsakan P; Ungkanont A; Angchaisuksiri P; Karntisaviwat K; Apilugsanachit A; Rerkamnuatchoke B; Jootar S; Nitiyanant P; Atichartakarn V
    Leuk Lymphoma; 2010 Nov; 51(11):2120-5. PubMed ID: 20846095
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.
    Carney DA; Westerman DA; Tam CS; Milner A; Prince HM; Kenealy M; Wolf M; Januszewicz EH; Ritchie D; Came N; Seymour JF
    Leukemia; 2010 Dec; 24(12):2056-62. PubMed ID: 20962860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia.
    Robertson LE; Estey E; Kantarjian H; Koller C; O'Brien S; Brown B; Keating MJ
    Leukemia; 1994 Dec; 8(12):2047-51. PubMed ID: 7807993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.
    Strati P; Wierda W; Burger J; Ferrajoli A; Tam C; Lerner S; Keating MJ; O'Brien S
    Cancer; 2013 Nov; 119(21):3805-11. PubMed ID: 23943357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
    Herishanu Y; Tadmor T; Braester A; Bairey O; Aviv A; Rahimi-Levene N; Fineman R; Levi I; Yuklea M; Ruchlemer R; Shvidel L; Polliack A
    Hematol Oncol; 2019 Apr; 37(2):185-192. PubMed ID: 30756414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997.
    Smith MR; Neuberg D; Flinn IW; Grever MR; Lazarus HM; Rowe JM; Dewald G; Bennett JM; Paietta EM; Byrd JC; Hussein MA; Appelbaum FR; Larson RA; Litzow MR; Tallman MS
    Blood; 2011 Sep; 118(13):3525-7. PubMed ID: 21803850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis.
    Michallet AS; Cazin B; Bouvet E; Oberic L; Schlaifer D; Mosser L; Salles G; Coiffier B; Laurent G; Ysebaert L
    J Geriatr Oncol; 2013 Apr; 4(2):141-7. PubMed ID: 24071539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
    Herling CD; Coombes KR; Benner A; Bloehdorn J; Barron LL; Abrams ZB; Majewski T; Bondaruk JE; Bahlo J; Fischer K; Hallek M; Stilgenbauer S; Czerniak BA; Oakes CC; Ferrajoli A; Keating MJ; Abruzzo LV
    Lancet Oncol; 2019 Nov; 20(11):1576-1586. PubMed ID: 31582354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL.
    Appleby N; O'Brien D; Quinn FM; Smyth L; Kelly J; Parker I; Scott K; Cahill MR; Crotty G; Enright H; Hennessy B; Hodgson A; Leahy M; O'Leary H; O'Dwyer M; Hayat A; Vandenberghe EA
    Leuk Lymphoma; 2018 Jun; 59(6):1338-1347. PubMed ID: 28925785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis.
    Nunes AA; da Silva AS; Souza KM; Koury Cde N; de Mello LM
    Crit Rev Oncol Hematol; 2015 Jun; 94(3):261-9. PubMed ID: 25797826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
    García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
    Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second cancers in chronic lymphocytic leukemia: growing importance in the era of improved treatment outcomes.
    Langerbeins P; Maurer C; Cramer P; Eichhorst B; Hallek M
    Leuk Lymphoma; 2015 Jun; 56(6):1575-6. PubMed ID: 25804766
    [No Abstract]   [Full Text] [Related]  

  • 20. Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group.
    Smolej L; Brychtová Y; Cmunt E; Doubek M; Špaček M; Belada D; Šimkovič M; Stejskal L; Zygulová I; Urbanová R; Brejcha M; Zuchnická J; Móciková H; Kozák T;
    Br J Haematol; 2021 May; 193(4):769-778. PubMed ID: 33618437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.